Sangamesh N C, Bajoria Atul A, Mishra Silpiranjan, Behera Sharmila, Sahoo Sanjay K, Bal Pratik Kumar
Oral Medicine and Radiology, Kalinga Institute of Dental Sciences, KIIT University, Bhubaneswar, Odisha, India.
Periodontics, Kalinga Institute of Dental Sciences, KIIT University, Patia, Bhubaneswar, Odisha, India.
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2197-S2198. doi: 10.4103/jpbs.jpbs_139_24. Epub 2024 May 1.
The study aimed to compare the effectiveness of carbamazepine and baclofen in the medical management of trigeminal neuralgia.
100 trigeminal neuralgia patients were randomly divided into two groups with 50 samples in each. Group A had patients treated with carbamazepine while Group B comprised of patients treated using baclofen. Follow-up was performed on the initial, 15 days, 1 month, and 3 months duration. The data was statistically evaluated.
Carbamazepine showed a "good response" in 54.39% of patients at initial follow-up, and adverse side effects increased in 20-29.49% of patients from the initial to 3-month duration. On the other hand, baclofen demonstrated a "good response" in 54.45% of patients at initial follow-up. At 800 mg, a "good response" was noted in 87.9% of patients, whereas 16.9% of patients had an "average response" and a "good response" after 1 month. At 3 months, 99.87% of patients showed a "good response." Both groups showed similar success rates after 3 months.
Adverse effects incidence and success were similar in both groups.
本研究旨在比较卡马西平和巴氯芬在三叉神经痛药物治疗中的有效性。
100例三叉神经痛患者随机分为两组，每组50例。A组患者接受卡马西平治疗，而B组患者接受巴氯芬治疗。在初始、15天、1个月和3个月时进行随访。对数据进行统计学评估。
在初始随访时，54.39%的患者对卡马西平表现出“良好反应”，从初始到3个月期间，20 - 29.49%的患者出现不良副作用增加。另一方面，在初始随访时，54.45%的患者对巴氯芬表现出“良好反应”。在800毫克剂量时，87.9%的患者在1个月后出现“良好反应”，而16.9%的患者出现“中等反应”，之后出现“良好反应”。在3个月时，99.87%的患者表现出“良好反应”。两组在3个月后成功率相似。
两组的不良反应发生率和成功率相似。
